Inhibrx, Inc. announced that Dr. Klaus Wagner, the Executive Vice President and Chief Medical Officer of Inhibrx, Inc. notified the Company of his intention to resign his position to pursue another opportunity. His departure is not due to any disagreement with the Company regarding its operations, policies, or procedures. His resignation will be effective as of February 1, 2022.

The Company expects to enter into an agreement with Dr. Wagner in connection with his departure to provide for, among other matters, a stock option exercise extension, a release and waiver of claims, and continued compliance with his confidentiality obligations.